Inaugural operating profit fails to lift 111 Inc.
The drug distributor expects to benefit from an ongoing crackdown on corruption in its industry due to the company’s focus on distribution to pharmacies rather than hospitals Key Takeaways: 111…
YI.US
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Trade-in ‘chic’ helps boost ATRenew to first operating profit
RERE.US
-
Its knuckles rapped, recovering Gaotu springs back to the black
GOTU.US
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Rebounding RLX plots course beyond China
RLX.US
Discover hidden China stock gems in our weekly newsletter